STERILE WATER IN PLASTIC CONTAINER Drug Patent Profile

Which patents cover Sterile Water In Plastic Container, and when can generic versions of Sterile Water In Plastic Container launch?

Sterile Water In Plastic Container is a drug marketed by B Braun, Baxter Hlthcare, Miles, and Otsuka Icu Medcl. and is included in five NDAs.

The generic ingredient in STERILE WATER IN PLASTIC CONTAINER is sterile water for irrigation. There are one thousand and seventy-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the sterile water for irrigation profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Sterile Water In Plastic Container

A generic version of STERILE WATER IN PLASTIC CONTAINER was approved as sterile water for irrigation by FRESENIUS KABI USA on August 12^th, 2024.

Summary for STERILE WATER IN PLASTIC CONTAINER

US Patents:	0
Applicants:	4
NDAs:	5
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	486
DailyMed Link:	STERILE WATER IN PLASTIC CONTAINER at DailyMed

US Patents and Regulatory Information for STERILE WATER IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
B Braun	STERILE WATER IN PLASTIC CONTAINER	sterile water for irrigation	LIQUID;IRRIGATION	016734-001	Approved Prior to Jan 1, 1982	AT	RX	Yes	No
Otsuka Icu Medcl	STERILE WATER IN PLASTIC CONTAINER	sterile water for irrigation	LIQUID;IRRIGATION	017513-001	Approved Prior to Jan 1, 1982	AT	RX	No	No
Baxter Hlthcare	STERILE WATER IN PLASTIC CONTAINER	sterile water for irrigation	LIQUID;IRRIGATION	017866-001	Approved Prior to Jan 1, 1982	AT	RX	No	No

Market Dynamics and Financial Trajectory for Sterile Water in Plastic Container

Last updated: February 19, 2026

What is the current market size and projected growth for sterile water in plastic containers?

The global market for sterile water in plastic containers is a significant segment within the broader pharmaceutical excipients and medical supplies industry. In 2023, the market was valued at an estimated USD 1.2 billion. Projections indicate a compound annual growth rate (CAGR) of 5.8% from 2024 to 2030, reaching an estimated USD 1.7 billion by the end of the forecast period. This growth is driven by increasing demand for parenteral drug formulations, rising healthcare expenditures, and the expanding use of single-dose and pre-filled injection systems.

The market can be segmented by application, container type, and end-user. Applications include intravenous (IV) solutions, irrigation, reconstitution of powdered drugs, and as a diluent for injectable medications. Plastic containers, predominantly high-density polyethylene (HDPE) and polyvinyl chloride (PVC), hold a substantial market share due to their flexibility, shatter resistance, and cost-effectiveness compared to glass alternatives. Key end-users are hospitals, clinics, diagnostic laboratories, and pharmaceutical manufacturers.

Geographically, North America and Europe currently dominate the market, accounting for over 60% of the global share. This is attributed to advanced healthcare infrastructure, high prevalence of chronic diseases requiring parenteral treatments, and established regulatory frameworks supporting the use of sterile water products. The Asia-Pacific region is anticipated to exhibit the highest growth rate, driven by increasing investments in healthcare facilities, expanding pharmaceutical production, and a growing population with greater access to medical services.

What are the primary drivers and restraints impacting market expansion?

Drivers:

• Increasing Demand for Parenteral Drug Administration: The rising incidence of chronic diseases such as diabetes, cardiovascular conditions, and cancer necessitates frequent parenteral administration of drugs. Sterile water for injection (SWFI) and sterile water for irrigation (SWFIrr) are fundamental components in these treatments, acting as diluents and carriers. Data from the World Health Organization (WHO) indicates a steady rise in the global burden of non-communicable diseases, directly translating to increased demand for injectable medications and their associated diluents [1].
• Growth in Biopharmaceuticals and Biosimilars: The biopharmaceutical sector is experiencing robust expansion, with a significant number of biologics requiring sterile aqueous solutions for reconstitution or dilution. The increasing development and approval of biosimilars further amplify this demand as they often mirror the complex formulation requirements of their reference products. Reports from market research firms project the global biopharmaceutical market to exceed USD 600 billion by 2025, a trend that directly fuels the need for high-purity sterile water [2].
• Advancements in Drug Delivery Systems: The adoption of advanced drug delivery systems, including pre-filled syringes (PFS), ready-to-use vials, and pre-mixed drug solutions, is growing. These systems often utilize sterile water as a primary component, simplifying administration for healthcare professionals and patients. The PFS market alone is projected to grow significantly, with an estimated value of over USD 10 billion by 2027 [3].
• Outpatient and Home Healthcare Trends: The shift towards outpatient procedures and the expansion of home healthcare services are increasing the demand for convenient and safe parenteral administration solutions. Sterile water in ready-to-use plastic containers is well-suited for these settings, offering ease of use and reduced risk of contamination.
• Technological Innovations in Plastic Container Manufacturing: Innovations in polymer science and manufacturing processes have led to the development of more advanced plastic containers that offer improved barrier properties, enhanced flexibility, and reduced leachables. The development of multi-layer plastics and specialized coatings addresses concerns regarding drug-container compatibility.

Restraints:

• Stringent Regulatory Requirements: The pharmaceutical industry operates under strict regulatory guidelines from bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Compliance with Good Manufacturing Practices (GMP), pharmacopeial standards (e.g., USP, EP), and quality control measures for sterile water production and packaging adds to manufacturing costs and complexity. Any deviation can lead to product recalls and significant financial penalties.
• Price Sensitivity and Competition: The market for sterile water in plastic containers is highly competitive, with numerous manufacturers globally. This intense competition can lead to price erosion, particularly for standard formulations, impacting profit margins for suppliers. The commoditized nature of basic sterile water can also limit pricing power.
• Concerns Regarding Plastic Leachables and Extractables: While plastic containers offer advantages, there are ongoing concerns and research regarding potential leachables and extractables that could migrate from the plastic into the sterile water, potentially affecting drug efficacy or patient safety. This necessitates rigorous testing and validation, adding to development and production costs. Regulatory bodies are continuously updating guidelines on this matter.
• Availability of Alternatives: In certain specific applications, alternative sterile diluents or solvents may be available, posing a competitive threat. However, sterile water remains the most universally accepted and cost-effective aqueous solvent for a vast array of parenteral formulations.

What is the competitive landscape and key player strategies?

The market for sterile water in plastic containers is characterized by a mix of large multinational pharmaceutical ingredient suppliers and specialized medical device manufacturers. Key players focus on product quality, regulatory compliance, supply chain reliability, and innovation in packaging technology.

Leading Companies and Their Strategies:

• Baxter International Inc.: A major player, Baxter focuses on a broad portfolio of sterile solutions, including intravenous fluids and diluents. Their strategy involves leveraging a strong global distribution network and a commitment to quality assurance. They invest in advanced manufacturing facilities to ensure compliance with international regulatory standards.
• B. Braun Melsungen AG: B. Braun offers a comprehensive range of IV products and medical devices. Their strategy centers on integrated solutions, providing not only the sterile water but also the associated administration systems. They emphasize product safety, innovation in drug delivery, and customer support.
• Fresenius Kabi AG: Known for its extensive range of infusion therapies, Fresenius Kabi is a significant supplier of sterile water solutions. Their focus is on manufacturing efficiency, product consistency, and expanding their market reach in emerging economies. They also invest in research to improve the shelf-life and stability of their products.
• ICU Medical, Inc.: ICU Medical has expanded its presence through strategic acquisitions in the IV solutions market. Their strategy involves integrating acquired product lines and optimizing manufacturing processes to enhance cost-effectiveness and market competitiveness. They aim to offer a reliable supply of essential intravenous products.
• Nipro Corporation: Nipro is a diversified medical device company that produces sterile water for injection and irrigation, particularly for dialysis and infusion therapy. Their strategy involves global expansion and maintaining high manufacturing standards to meet the demands of diverse healthcare systems.
• Otsuka Pharmaceutical Factory, Inc.: A subsidiary of Otsuka Holdings, this company is a significant producer of intravenous solutions. Their strategic focus is on research and development of advanced formulations and packaging solutions to meet evolving clinical needs.

Key Strategies Employed by Market Participants:

• Vertical Integration: Some companies integrate their operations from raw material sourcing to final product manufacturing and distribution, allowing for greater control over quality and cost.
• Strategic Partnerships and Acquisitions: Companies pursue mergers, acquisitions, and strategic alliances to expand their product portfolios, gain access to new markets, and acquire specialized technologies.
• Investment in R&D for Packaging Innovations: Significant investment is directed towards developing novel plastic container designs that offer improved drug compatibility, enhanced user convenience, and better environmental profiles. This includes exploring advanced polymers and barrier technologies.
• Focus on Regulatory Compliance and Quality Assurance: Maintaining robust quality management systems and adhering to stringent regulatory standards (USP, EP, JP, FDA, EMA) is paramount. Companies invest in advanced analytical testing and validation to ensure product purity and safety.
• Global Expansion and Market Penetration: Companies actively seek to increase their market share in both developed and emerging economies through direct sales, distribution agreements, and establishing local manufacturing presence where feasible.

What are the patent landscapes and intellectual property considerations?

The patent landscape for sterile water in plastic containers primarily revolves around innovations in container design, material composition, sterilization processes, and formulations that enhance stability or delivery. While sterile water itself is a well-established commodity, intellectual property is typically associated with advancements that improve its delivery, purity, stability, or manufacturing efficiency.

Key Areas of Patent Activity:

• Container Design and Material Science: Patents are often filed for novel plastic container structures that offer enhanced barrier properties against oxygen or moisture, improved flexibility, tamper-evident sealing mechanisms, or ergonomic designs for easier handling and administration. This includes research into specific polymer blends, multi-layer constructions, and additive packages that prevent plastic degradation or interaction with the sterile water. For example, patents might cover specific HDPE formulations with enhanced impact resistance or PVC compositions with optimized plasticizer levels to minimize extractables.
• Sterilization Technologies: While terminal sterilization (e.g., autoclaving) is common, patents may exist for novel or improved methods of sterilization that ensure sterility without compromising the integrity of the plastic container or the purity of the water. This could include advanced filtration techniques or alternative radiation-based methods validated for specific plastic materials.
• Formulation Enhancements: While the product is primarily water, patents may cover formulations that include specific trace amounts of stabilizers or buffers if their use is intended to maintain the quality or efficacy of a drug reconstituted with the sterile water. However, patents for sterile water alone are rare; IP typically protects the application or delivery system using sterile water.
• Manufacturing Processes: Patents can protect specific manufacturing processes that ensure high purity, reduce contamination risks during filling and sealing, or optimize the overall production efficiency for sterile water in plastic containers. This might involve patented filling technologies, unique capping mechanisms, or advanced quality control monitoring systems integrated into the production line.
• Combination Products and Delivery Devices: A significant area of IP involves the integration of sterile water with drug products into single-use or pre-filled delivery systems. Patents in this domain protect the entire device, including the container holding the sterile water, the drug, and the mechanism for mixing or administration. These patents are crucial for companies developing ready-to-use injection systems.

Intellectual Property Considerations for Businesses:

• Freedom-to-Operate (FTO) Analysis: Before launching new products or manufacturing processes, thorough FTO analyses are essential to ensure that they do not infringe on existing patents. This involves comprehensive searches of patent databases.
• Patent Monitoring: Continuous monitoring of patent filings and grants in the relevant technological areas (e.g., medical plastics, sterile solutions, drug delivery devices) is crucial for identifying potential threats or licensing opportunities.
• Strategic Patent Filing: Companies should consider filing patents for their own innovations in container technology, manufacturing processes, or novel applications of sterile water to secure market exclusivity and create licensing revenue streams.
• Licensing and Cross-Licensing: Opportunities may exist to license patented technologies from other entities or to engage in cross-licensing agreements to gain access to essential IP.
• Trade Secrets: Certain aspects of manufacturing processes, quality control protocols, or supplier relationships that provide a competitive advantage but are not patentable may be protected as trade secrets.

The patent landscape is dynamic, reflecting ongoing innovation in materials science, drug delivery, and pharmaceutical manufacturing. Companies that actively manage their IP portfolio and conduct diligent FTO analyses are better positioned to navigate this complex environment and protect their market position.

Key Takeaways

The sterile water in plastic container market is projected for steady growth, driven by the expanding use of parenteral drugs and advancements in delivery systems. Key drivers include chronic disease prevalence and the biopharmaceutical sector's expansion. Regulatory compliance and price competition represent significant restraints. Leading companies employ strategies focused on quality, integrated solutions, and global expansion. Intellectual property in this sector is concentrated on container design, material science, and manufacturing processes, necessitating robust IP management for market participants.

Frequently Asked Questions

1. What are the primary types of plastic used for sterile water containers? High-density polyethylene (HDPE) and polyvinyl chloride (PVC) are the most common plastics due to their cost-effectiveness, flexibility, and shatter resistance. Other specialized polymers may be used for specific applications requiring enhanced barrier properties or reduced leachables.

2. What are the key quality standards that sterile water in plastic containers must meet? Products must comply with pharmacopeial standards such as the United States Pharmacopeia (USP), European Pharmacopoeia (EP), and Japanese Pharmacopoeia (JP). These standards dictate requirements for water purity, sterility, endotoxin levels, and container integrity.

3. How does the regulatory environment impact manufacturers of sterile water in plastic containers? Manufacturers must adhere to Good Manufacturing Practices (GMP) and obtain necessary approvals from regulatory bodies like the FDA and EMA. Compliance involves rigorous quality control, validation of manufacturing processes, and detailed documentation, which can increase production costs and timelines.

4. What are the main differences between sterile water for injection (SWFI) and sterile water for irrigation (SWFIrr)? While both are sterile water, SWFI has more stringent purity requirements, including extremely low levels of endotoxins, as it is intended for parenteral administration. SWFIrr, used for wound cleansing or irrigation during surgery, also requires sterility but may have slightly less restrictive endotoxin limits.

5. What are the future trends expected in the packaging of sterile water? Future trends include the development of more sustainable plastic materials, enhanced barrier properties to improve shelf-life, smart packaging technologies for improved tracking and authentication, and designs that further facilitate ease of use in home healthcare settings.

Citations

[1] World Health Organization. (n.d.). Noncommunicable diseases. Retrieved from https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases [2] Various Market Research Reports (e.g., Grand View Research, Mordor Intelligence, Allied Market Research) on the global biopharmaceutical market, 2023-2024. [3] Various Market Research Reports (e.g., Pre-filled Syringes Market Size, Share & Trends Analysis Report, 2023-2030), 2023-2024.